FMP
Kazia Therapeutics Limited
KZIA
NASDAQ
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
3.02 USD
-0.07 (-2.32%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. John Edwin Friend II, M.D.
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
CIK
0001075880
ISIN
US48669G1058
CUSIP
48669G105
Address
Three International Towers
Phone
1300 787 272
Country
AU
Employee
9
IPO Date
Jan 6, 1999
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
KZIA Financial Summary
CIK
0001075880
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
48669G105
ISIN
US48669G1058
Country
AU
Price
3.02
Beta
2.08
Volume Avg.
121.39k
Market Cap
10.05M
Shares
-
52-Week
1.9-15.8
DCF
0.12
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.47
P/B
-
Website
https://www.kaziatherapeutics.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest KZIA News
It looks like there's no news available.
